Insider: Francois Cedric Chief Executive Officer - Apellis Pharmaceuticals, Inc.
| Company Holdings |
| Direct | Indirect Ownership | Total | |
| Shares | 331,605 | 307,946 | 639,551 |
| Value | $7,418,003.85 | $6,888,752.02 | $14,306,755.87 |
Trans. Date |
Trans. Type |
Shares |
Ownership Type |
Issue Type |
Price |
Trans. Value |
Total Shares Owned |
|---|---|---|---|---|---|---|---|
| 08/28/2025 | DDS | 49,963 | Indirect | COM | $28.39 | $1,418,449.57 | 307,946 |
| 08/27/2025 | DDS | 175,037 | Indirect | COM | $28.19 | $4,934,293.03 | 357,909 |
| 07/17/2025 | DDS | 19,725 | Direct | COM | $20.21 | $398,734.96 | 331,605 |
| 07/15/2025 | DDS | 1,900 | Direct | COM | $20.09 | $38,167.96 | 342,333 |
| 07/14/2025 | DDS | 137,465 | Direct | COM | $20.19 | $2,774,923.48 | 343,433 |
| 01/29/2025 | DDS | 2,824 | Direct | COM | $29.52 | $83,374.65 | 415,695 |
| 01/22/2025 | DDS | 13,551 | Direct | COM | $30.43 | $412,295.95 | 418,519 |
| 01/17/2025 | DDS | 6,007 | Direct | COM | $29.96 | $179,958.91 | 301,408 |
| 01/13/2025 | DDS | 6,247 | Direct | COM | $28.70 | $179,302.02 | 307,415 |
| 03/01/2024 | DDS | 41,704 | Direct | COM | $62.96 | $2,625,813.12 | 493,090 |
| 03/01/2024 | DDS | 28,868 | Direct | COM | $62.21 | $1,795,964.88 | 534,794 |
| 03/01/2024 | DDS | 116,512 | Direct | COM | $64.92 | $7,563,527.95 | 314,075 |
| 03/01/2024 | DDS | 413 | Direct | COM | $65.68 | $27,125.84 | 313,662 |
| 03/01/2024 | DDS | 62,503 | Direct | COM | $64.26 | $4,016,274.02 | 430,587 |
| 02/12/2024 | DDS | 3,962 | Direct | COM | $67.77 | $268,492.46 | 313,662 |
| 01/29/2024 | DDS | 2,843 | Direct | COM | $64.14 | $182,344.90 | 317,624 |
| 01/22/2024 | DDS | 13,431 | Direct | COM | $65.00 | $872,961.28 | 320,467 |
| 01/16/2024 | DDS | 7,851 | Direct | COM | $66.81 | $524,514.32 | 333,898 |
| 11/21/2023 | DDS | 5,000 | Direct | COM | $48.80 | $244,000.00 | 269,655 |
| 09/01/2023 | DDS | 139,716 | Direct | COM | $41.70 | $5,826,506.49 | 434,939 |
| 09/01/2023 | DDS | 10,284 | Direct | COM | $42.44 | $436,452.96 | 424,655 |
| 05/16/2023 | DDS | 1,800 | Direct | COM | $83.85 | $150,921.00 | 301,921 |
| 05/16/2023 | DDS | 934 | Direct | COM | $83.17 | $77,681.81 | 303,721 |
| 05/16/2023 | DDS | 14,611 | Direct | COM | $85.01 | $1,242,065.04 | 287,310 |
| 05/16/2023 | DDS | 2,120 | Direct | COM | $87.67 | $185,868.67 | 274,655 |
| 1 2 3 Next Last You are at page 1 of 3 pages |
|
Transaction Type Key First letter: A = Acquired, D = Disposed Second letter: A = Grant, award or other acquisition pursuant to Rule 16b-3(d) C = Conversion of derivative security | D = Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | E = Expiration of short derivative position | F = Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. | G = Gift | H = Expiration (or cancellation) of long derivative position with value received | I = Discretionary transaction in accordance with Rule 16b-3(f) | J = Other | L = Small acquisition under Rule 16a-6 | M = Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | O = Exercise of out-of-the-money derivative security | P = Open market or private purchase | S = Open market or private sale | U = Disposition pursuant to a tender of shares in a change of control transaction | W = Acquisition or disposition by will or the laws of descent and distribution | X = Exercise of in-the-money or at-the-money derivative security | Z = Deposit into or withdrawal from voting trust |
 |
Send to Excel |
© 2000 - 2025 Zacks Investment Research